Barbora D.
- Country
- Czechia
- Department
- Klinika hematoonkologie
Research Overview
- Evaluation of an IDH1m Inhibitor in Patients with IDH1-Mutated Malignancies and Hepatic or Renal Impairment
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- Phase 3 Study of Quizartinib with Chemotherapy in FLT3-ITD Negative Acute Myeloid Leukemia Patients
Data & Insights
Has run more than one trial at 76 of 202 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of acute myeloid leukemia (AML), with particular focus on developing innovative therapeutic approaches for newly diagnosed patients.
- FLT3-ITD negative leukemia management
- Combination therapy strategies
- Maintenance treatment protocols
Research interests encompass targeted therapies in combination with standard chemotherapy regimens for blood cancers.
Treatment Innovation
The investigator explores novel therapeutic combinations incorporating targeted molecular agents with conventional chemotherapy approaches in hematologic malignancies.
- Chemotherapy optimization
- Novel drug combinations
- Long-term treatment strategies
Focus includes evaluation of treatment outcomes in specific genetic subtypes of leukemia.
Clinical Outcomes
Primary research interest centers on improving overall survival in acute myeloid leukemia through innovative treatment approaches.
- Survival outcome assessment
- Treatment response evaluation
- Long-term patient monitoring
Expertise includes assessment of therapeutic efficacy in various treatment phases including induction, consolidation, and maintenance.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.